The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

This study is currently recruiting participants.
Verified October 2013 by Meir Medical Center
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01809574
First received: March 10, 2013
Last updated: October 6, 2013
Last verified: October 2013
  Purpose

We hypothesized that the multi-disciplinary assessment of interstitial lung disease patients would lead to a more accurate diagnosis and consequently alterations in treatment regimens that may lead to improved outcomes.


Condition
Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis
Connective Tissue Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • The number of patients with collagen related pulmonary fibrosis that are diagnosed by Rheumatologists compared to Pulmonologists. [ Time Frame: two years ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: May 2013
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

60 patients that will refer to the pulmonary outpatient or inpatients department for evaluation due to ILD will be included

Criteria

Inclusion Criteria:

  • Age above 18 years old
  • ILD according to ATS/ERS guidelines
  • Signed inform consent

Exclusion Criteria:

  • Previous lung surgery
  • Other significant systemic disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01809574

Contacts
Contact: David Shitrit, Dr. 097471556 davids3@clalit.org.il

Locations
Israel
Meir Medical Center Recruiting
Kfar Saba, Israel, 972
Contact: David Shitrit, Dr    09-7471556    davids3@clalit.org.il   
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: David Shitrit, Dr Head of Pulmonary departmant, Meir Medical Center.
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01809574     History of Changes
Other Study ID Numbers: 225-12-MMC
Study First Received: March 10, 2013
Last Updated: October 6, 2013
Health Authority: Israel: Ethics Commission

Keywords provided by Meir Medical Center:
Interstitial lung disease
Idiopathic pulmonary fibrosis
Connective tissue disease

Additional relevant MeSH terms:
Connective Tissue Diseases
Fibrosis
Lung Diseases
Pulmonary Fibrosis
Lung Diseases, Interstitial
Idiopathic Pulmonary Fibrosis
Pathologic Processes
Respiratory Tract Diseases
Idiopathic Interstitial Pneumonias

ClinicalTrials.gov processed this record on April 15, 2014